Subtopic Deep Dive
Newcastle Disease Virus Oncology
Research Guide
What is Newcastle Disease Virus Oncology?
Newcastle Disease Virus Oncology uses NDV as an oncolytic agent that selectively replicates in and lyses cancer cells while stimulating antitumor immunity.
NDV, an avian paramyxovirus, shows tumor-selective replication due to defective antiviral responses in cancer cells (Zamarin and Palese, 2012). Phase I trials with PV701, a replication-competent NDV strain, demonstrated safety and tumor regression in advanced solid cancers after intravenous dosing (Pecora et al., 2002). Over 20 papers document NDV's mechanisms and clinical potential, with foundational work tracing to 1965 (Cassel and Garrett, 1965).
Why It Matters
NDV offers a low-cost, safe oncolytic virotherapy for cancers unresponsive to standard treatments, as shown in PV701 trials where intravenous doses regressed xenografts without severe toxicity (Pecora et al., 2002). Zamarin and Palese (2012) highlight NDV's immune stimulation via interferon induction, enhancing T-cell responses against tumors. Early studies like Cassel and Garrett (1965) established NDV's antineoplastic effects, supporting ongoing trials combining NDV with checkpoint inhibitors for broader immunotherapy applications.
Key Research Challenges
Tumor Delivery Barriers
Intravenous NDV faces neutralization by host antibodies and poor vascular penetration in solid tumors (Pecora et al., 2002). Zamarin and Palese (2012) note that complement evasion strategies are needed, as viruses trigger innate responses limiting systemic spread (Agrawal et al., 2017).
Immune Evasion in Tumors
Cancer cells' defective interferon signaling enables NDV replication but requires balancing oncolysis with adaptive immunity induction (Zamarin and Palese, 2012). Clinical data show transient viremia without sustained antitumor effects in some patients (Pecora et al., 2002).
Viral Fusion Optimization
Paramyxovirus F protein fusion must be tuned for tumor cell entry without off-target effects (Lambert et al., 1996). NDV strains vary in entry efficiency, complicating strain selection for therapy (Dimitrov, 2004).
Essential Papers
Virus entry: molecular mechanisms and biomedical applications
Dimiter S. Dimitrov · 2004 · Nature Reviews Microbiology · 684 citations
Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers
Andrew L. Pecora, Naiyer A. Rizvi, Gary I. Cohen et al. · 2002 · Journal of Clinical Oncology · 386 citations
PURPOSE: PV701, a replication-competent strain of Newcastle disease virus, causes regression of tumor xenografts after intravenous administration. This phase I study was designed to define the maxi...
Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion.
D.M. Lambert, Shawn Barney, Anick Lambert et al. · 1996 · Proceedings of the National Academy of Sciences · 331 citations
The synthetic peptides DP-107 and DP-178 (T-20), derived from separate domains within the human immunodeficiency virus type 1 (HIV-1) transmembrane (TM) protein, gp4l, are stable and potent inhibit...
Host Cell Entry of Respiratory Syncytial Virus Involves Macropinocytosis Followed by Proteolytic Activation of the F Protein
Magdalena A. Krzyzaniak, Michael Zumstein, Juan Gerez et al. · 2013 · PLoS Pathogens · 271 citations
Respiratory Syncytial Virus (RSV) is a highly pathogenic member of the Paramyxoviridae that causes severe respiratory tract infections. Reports in the literature have indicated that to infect cells...
Oncolytic Newcastle Disease Virus for Cancer Therapy: Old Challenges and New Directions
Dmitriy Zamarin, Peter Palese · 2012 · Future Microbiology · 263 citations
Newcastle disease virus (NDV) is an avian paramyxovirus, which has been demonstrated to possess significant oncolytic activity against mammalian cancers. This review summarizes the research leading...
Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed
Vincent H. J. Léonard, Patrick L. Sinn, Gregory Hodge et al. · 2008 · Journal of Clinical Investigation · 235 citations
The current model of measles virus (MV) pathogenesis implies that apical infection of airway epithelial cells precedes systemic spread. An alternative model suggests that primarily infected lymphat...
Newcastle disease virus as an antineoplastic agent
William A. Cassel, R. Earl Garrett · 1965 · Cancer · 218 citations
Reading Guide
Foundational Papers
Start with Cassel and Garrett (1965) for original antineoplastic evidence, Pecora et al. (2002) for phase I PV701 safety data, and Zamarin and Palese (2012) for mechanisms summarizing 50 years of NDV oncology.
Recent Advances
Study Brown and Bevins (2017) on viral persistence for strain safety and Wang et al. (2023) on viral vectors for NDV vaccine combos in cancer therapy.
Core Methods
Core techniques: tumor-selective replication via interferon defects (Zamarin and Palese, 2012), F protein-mediated fusion entry (Lambert et al., 1996; Dimitrov, 2004), and intravenous dosing in trials (Pecora et al., 2002).
How PapersFlow Helps You Research Newcastle Disease Virus Oncology
Discover & Search
Research Agent uses searchPapers and citationGraph to map NDV oncology literature from Zamarin and Palese (2012), revealing 263 citations linking to Pecora et al. (2002) phase I trials; exaSearch uncovers wild bird persistence data relevant to strain safety (Brown and Bevins, 2017); findSimilarPapers expands to paramyxovirus fusion inhibitors.
Analyze & Verify
Analysis Agent employs readPaperContent on Pecora et al. (2002) to extract MTD data from PV701 trials, verifies claims with CoVe against Zamarin and Palese (2012) mechanisms, and runs PythonAnalysis to plot dose-response curves from trial stats using pandas; GRADE grading scores evidence as high for safety in advanced cancers.
Synthesize & Write
Synthesis Agent detects gaps in NDV combination therapies post-Pecora et al. (2002), flags contradictions between early (Cassel and Garrett, 1965) and modern immune data; Writing Agent uses latexEditText and latexSyncCitations to draft trial reviews citing 386-citation Pecora paper, latexCompile generates figures, exportMermaid visualizes oncolytic mechanisms.
Use Cases
"Analyze survival data from PV701 NDV phase I trial."
Analysis Agent → readPaperContent (Pecora et al., 2002) → runPythonAnalysis (pandas survival curves) → matplotlib plot of MTD vs. response.
"Write LaTeX review of NDV oncolytic mechanisms."
Synthesis Agent → gap detection (Zamarin and Palese, 2012) → Writing Agent → latexEditText + latexSyncCitations (Pecora et al.) → latexCompile PDF.
"Find code for NDV fusion protein modeling."
Research Agent → paperExtractUrls (Lambert et al., 1996) → paperFindGithubRepo → githubRepoInspect (F protein simulation scripts).
Automated Workflows
Deep Research workflow scans 50+ NDV papers via citationGraph from Zamarin and Palese (2012), producing structured reports on trial outcomes like Pecora et al. (2002). DeepScan applies 7-step CoVe to verify oncolytic claims against Cassel and Garrett (1965), with GRADE checkpoints. Theorizer generates hypotheses on NDV-checkpoint inhibitor combos from immune evasion papers (Agrawal et al., 2017).
Frequently Asked Questions
What defines Newcastle Disease Virus Oncology?
It applies NDV as an oncolytic virus that replicates selectively in cancer cells due to their interferon defects, lysing tumors and inducing immunity (Zamarin and Palese, 2012).
What methods characterize NDV oncolysis?
Key methods include intravenous PV701 dosing in phase I trials (Pecora et al., 2002) and F protein fusion for entry (Lambert et al., 1996), with mechanisms reviewed in Zamarin and Palese (2012).
What are key papers in this field?
Pecora et al. (2002, 386 citations) reports phase I PV701 trials; Zamarin and Palese (2012, 263 citations) reviews mechanisms; Cassel and Garrett (1965, 218 citations) establishes antineoplastic use.
What open problems exist?
Challenges include systemic delivery past antibodies (Pecora et al., 2002), optimizing fusion for tumor specificity (Dimitrov, 2004), and sustaining immune responses (Zamarin and Palese, 2012).
Research Virology and Viral Diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Newcastle Disease Virus Oncology with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Virology and Viral Diseases Research Guide